These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 12084903)

  • 1. Liver and thyroid function and autoimmunity during interferon-beta 1b treatment for multiple sclerosis.
    Tremlett H
    Neurology; 2002 Jun; 58(12):1868. PubMed ID: 12084903
    [No Abstract]   [Full Text] [Related]  

  • 2. Lethal capillary leak syndrome after a single administration of interferon beta-1b.
    Niederwieser G
    Neurology; 2000 Apr; 54(7):1545-6. PubMed ID: 10751284
    [No Abstract]   [Full Text] [Related]  

  • 3. Liver and thyroid function and autoimmunity during interferon-beta 1b treatment for MS.
    Durelli L; Ferrero B; Oggero A; Verdun E; Ghezzi A; Montanari E; Zaffaroni M;
    Neurology; 2001 Oct; 57(8):1363-70. PubMed ID: 11673572
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Appearance of immune thyroid diseases during beta-interferon therapy of multiple sclerosis].
    Buchinger W; Niederwieser G; Rainer F
    Dtsch Med Wochenschr; 1999 Dec; 124(48):1473. PubMed ID: 10615332
    [No Abstract]   [Full Text] [Related]  

  • 5. Panniculitis and lipoatrophy after subcutaneous injection of interferon beta-1b in a patient with multiple sclerosis.
    O'Sullivan SS; Cronin EM; Sweeney BJ; Bourke JF; Fitzgibbon J
    J Neurol Neurosurg Psychiatry; 2006 Dec; 77(12):1382-3. PubMed ID: 16782776
    [No Abstract]   [Full Text] [Related]  

  • 6. [Interferon beta-1b retinopathy during a treatment for multiple sclerosis].
    Sommer S; Sablon JC; Zaoui M; Rozot P; Hosni A
    J Fr Ophtalmol; 2001 May; 24(5):509-12. PubMed ID: 11397988
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glatiramer acetate induced acute exacerbation of autoimmune hepatitis in a patient with multiple sclerosis.
    Neumann H; Csepregi A; Sailer M; Malfertheiner P
    J Neurol; 2007 Jun; 254(6):816-7. PubMed ID: 17351724
    [No Abstract]   [Full Text] [Related]  

  • 8. Autoantibodies in multiple sclerosis patients before and during IFN-beta 1b treatment: are they correlated with the occurrence of autoimmune diseases?
    Verdun E; Isoardo G; Oggero A; Ferrero B; Ghezzi A; Montanari E; Zaffaroni M; Durelli L;
    J Interferon Cytokine Res; 2002 Feb; 22(2):245-55. PubMed ID: 11911808
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [A short history of beta-interferon therapy of multiple sclerosis].
    Stock G; Horowski R
    Med Klin (Munich); 2001 Sep; 96 Suppl 1():3-9. PubMed ID: 11603113
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thyroid function and autoimmunity during interferon beta-1b treatment: a multicenter prospective study.
    Durelli L; Ferrero B; Oggero A; Verdun E; Ghezzi A; Montanari E; Zaffaroni M;
    J Clin Endocrinol Metab; 2001 Aug; 86(8):3525-32. PubMed ID: 11502774
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Local reactions associated with subcutaneous injections of both beta-interferon 1a and 1b.
    García-F-Villalta M; Daudén E; Sánchez J; Fraga J; Ramo C; García-Díez A
    Acta Derm Venereol; 2001 May; 81(2):152. PubMed ID: 11501663
    [No Abstract]   [Full Text] [Related]  

  • 12. Arthritis during interferon beta-1b treatment in multiple sclerosis.
    Altintas A; Alici Y; Melikoğlu M; Siva A
    Mult Scler; 2002 Dec; 8(6):534-6. PubMed ID: 12474998
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An open labelled assessment of adverse effects associated with interferon 1-beta in the treatment of multiple sclerosis.
    Ozuma J
    J Neurosci Nurs; 1996 Apr; 28(2):72. PubMed ID: 8718753
    [No Abstract]   [Full Text] [Related]  

  • 14. Drug induced liver injury secondary to interferon-beta (IFN-beta) in multiple sclerosis.
    Byrnes V; Afdhal N; Challies T; Greenstein PE
    Ann Hepatol; 2006; 5(1):56-9. PubMed ID: 16531969
    [TBL] [Abstract][Full Text] [Related]  

  • 15. C1-inhibitor activity and plasma concentrations in patients with monoclonal gammopathies: implications for treatment with recombinant interferon-beta 1b.
    Schmidt S; Schneider T; Schmidt-Wolf I; Ko Y; Schlegel U; Klockgether T; Hertfelder HJ
    Mult Scler; 2004 Apr; 10(2):243-4. PubMed ID: 15124772
    [No Abstract]   [Full Text] [Related]  

  • 16. Acute acneiform eruption induced by interferon beta-1b during treatment for multiple sclerosis.
    Rosa DJ; Matias Fde A; Cedrim SD; Machado RF; Sá AA; Silva VC
    An Bras Dermatol; 2011; 86(2):336-8. PubMed ID: 21603818
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Therapy of multiple sclerosis with interferon-beta-1b. Educating the patient and managing side-effects].
    Walther EU; Dietrich E; Hohlfeld R
    Nervenarzt; 1996 Jun; 67(6):452-6. PubMed ID: 8767199
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Autoimmune hepatitis and interferon beta-1a for multiple sclerosis.
    Duchini A
    Am J Gastroenterol; 2002 Mar; 97(3):767-8. PubMed ID: 11922585
    [No Abstract]   [Full Text] [Related]  

  • 19. Onset of myasthenia gravis in a patient with multiple sclerosis during interferon-1b treatment.
    Blake G; Murphy S
    Neurology; 1997 Dec; 49(6):1747-8. PubMed ID: 9409387
    [No Abstract]   [Full Text] [Related]  

  • 20. A single-center, randomized, double-blind, placebo-controlled study of interferon beta-1b on primary progressive and transitional multiple sclerosis.
    Montalban X; Sastre-Garriga J; Tintoré M; Brieva L; Aymerich FX; Río J; Porcel J; Borràs C; Nos C; Rovira A
    Mult Scler; 2009 Oct; 15(10):1195-205. PubMed ID: 19797261
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.